{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:36:51Z","timestamp":1794670611742,"version":"4.9.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although the use of treosulfan (TREO) in conventional donor hematopoietic cell transplantation (HCT) has been extensively evaluated, its use in cord blood transplantation (CBT) for hematologic malignancies has not been reported. Between March 2009 and October 2019, 130 CBT recipients were enrolled in this prospective multicenter phase 2 study. The conditioning regimen consisted of TREO, fludarabine, and a single fraction of 2 Gy total-body irradiation. Cyclosporine and mycophenolate mofetil were used for graft-versus-host disease prophylaxis. The primary end point was incidence of graft failure (GF), and based on risk of GF, patients were classified as low risk (arm 1, n = 66) and high risk (arm 2, n = 64). The median age was 45 years (range, 0.6-65 years). Disease status included acute leukemias in first complete remission (CR; n = 56), in \u22652 CRs (n = 46), and myelodysplastic (n = 25) and myeloproliferative syndromes (n = 3). Thirty-five patients (27%) had received a prior HCT. One hundred twenty-three patients (95%) engrafted, with neutrophil recovery occurring at a median of 19 days for patients on arm 1 and 20 days for patients on arm 2. The 3-year overall survival, relapse-free survival (RFS), transplant-related mortality, and relapse for the combined groups were 66%, 57%, 18%, and 24%, respectively. Among patients who had a prior HCT, RFS at 3 years was 48%. No significant differences in clinical outcomes were seen between the 2 arms. Our results demonstrate that TREO-based conditioning for CBT recipients is safe and effective in promoting CB engraftment with favorable clinical outcomes. This trial was registered at www.clinicaltrials.gov as #NCT00796068.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002222","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T15:38:48Z","timestamp":1595605128000},"page":"3302-3310","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-2159","authenticated-orcid":false,"given":"Filippo","family":"Milano","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, School of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Gutman","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Colorado, Denver, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-9023","authenticated-orcid":false,"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, School of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7422-2763","authenticated-orcid":false,"given":"Eneida R.","family":"Nemecek","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Baumgart","sequence":"additional","affiliation":[{"name":"Medac GmbH, Wedel, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-9834","authenticated-orcid":false,"given":"Laurel","family":"Thur","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2460-1911","authenticated-orcid":false,"given":"Ann","family":"Dahlberg","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Pediatrics, School of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4060-9393","authenticated-orcid":false,"given":"Rachel B.","family":"Salit","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, School of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1769-7388","authenticated-orcid":false,"given":"Corinne","family":"Summers","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Pediatrics, School of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1839-5069","authenticated-orcid":false,"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Medicine, School of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1044-2801","authenticated-orcid":false,"given":"Colleen","family":"Delaney","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Pediatrics, School of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"issue":"5","key":"2020072411361806900_B1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2002.v8.pm12064362","article-title":"Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow","volume":"8","author":"Barker","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020072411361806900_B2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM199607183350303","article-title":"Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients","volume":"335","author":"Kurtzberg","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"2020072411361806900_B3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM199708073370602","article-title":"Outcome of cord-blood transplantation from related and unrelated donors","volume":"337","author":"Gluckman","year":"1997","journal-title":"N Engl J Med"},{"issue":"22","key":"2020072411361806900_B4","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199811263392201","article-title":"Outcomes among 562 recipients of placental-blood transplants from unrelated donors","volume":"339","author":"Rubinstein","year":"1998","journal-title":"N Engl J Med"},{"issue":"10","key":"2020072411361806900_B5","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbmt.2004.06.017","article-title":"Comparison of unrelated cord blood and unrelated bone marrow transplants for adults with leukemia a collaborative study: the New York Blood Center National Cord Blood Program and the International Bone Marrow Transplant Registry","volume":"10","author":"Laughlin","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020072411361806900_B6","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood-2002-01-0294","article-title":"Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival","volume":"100","author":"Wagner","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2020072411361806900_B7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2020072411361806900_B8","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.bbmt.2015.07.029","article-title":"High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with T cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia","volume":"21","author":"Ponce","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020072411361806900_B9","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2009.05.014","article-title":"Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis","volume":"15","author":"Gutman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020072411361806900_B10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020072411361806900_B11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.bbmt.2017.12.776","article-title":"Intravenous busulfan compared with treosulfan-based conditioning for allogeneic stem cell transplantation in acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation","volume":"24","author":"Shimoni","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020072411361806900_B12","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"2020072411361806900_B13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00280-007-0669-3","article-title":"Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients","volume":"62","author":"Munkelt","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2020072411361806900_B14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bbmt.2017.11.009","article-title":"Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience","volume":"24","author":"Slatter","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020072411361806900_B15","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.bbmt.2018.04.025","article-title":"Treosulfan, fludarabine, and low-dose total body irradiation for children and young adults with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation: prospective phase II trial of the Pediatric Blood and Marrow Transplant Consortium","volume":"24","author":"Nemecek","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020072411361806900_B16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbmt.2008.02.016","article-title":"Myeloablative intravenous busulfan\/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients","volume":"14","author":"Horwitz","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020072411361806900_B17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","article-title":"Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"issue":"20","key":"2020072411361806900_B18","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.1182\/blood-2011-06-361618","article-title":"Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients","volume":"118","author":"Milano","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2020072411361806900_B19","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020072411361806900_B20","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020072411361806900_B21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2141.2008.07385.x","article-title":"Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major","volume":"143","author":"Bernardo","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"2020072411361806900_B22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/sj.bmt.1705605","article-title":"Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma","volume":"39","author":"Schmidt-Hieber","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2020072411361806900_B23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2008.07179.x","article-title":"Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"2020072411361806900_B24","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","article-title":"Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial","volume":"96","author":"Ruutu","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2020072411361806900_B25","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2017.12.785","article-title":"Transplant conditioning with treosulfan\/fludarabine with or without total body irradiation: a randomized phase II trial in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"24","author":"Deeg","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020072411361806900_B26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/bmt.2012.243","article-title":"Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin","volume":"48","author":"Ostronoff","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2020072411361806900_B27","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2010-05-285304","article-title":"Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood","volume":"116","author":"Brunstein","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020072411361806900_B28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm.2080","article-title":"Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution","volume":"16","author":"Delaney","year":"2010","journal-title":"Nat Med"},{"issue":"5","key":"2020072411361806900_B29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.bbmt.2013.02.007","article-title":"A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation","volume":"19","author":"Ponce","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020072411361806900_B30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bmt.2010.192","article-title":"Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis","volume":"46","author":"Cutler","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2020072411361806900_B31","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/10428194.2011.631159","article-title":"Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant","volume":"53","author":"Ciurea","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2020072411361806900_B32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bbmt.2008.09.021","article-title":"Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival","volume":"14","author":"Kumar","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020072411361806900_B33","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2008-03-147041","article-title":"Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia","volume":"113","author":"Atsuta","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2020072411361806900_B34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bbmt.2015.09.014","article-title":"The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review","volume":"22","author":"Chaudhry","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020072411361806900_B35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbmt.2006.08.041","article-title":"Double unrelated reduced-intensity umbilical cord blood transplantation in adults","volume":"13","author":"Ballen","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020072411361806900_B36","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2007-04-067215","article-title":"Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease","volume":"110","author":"Brunstein","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2020072411361806900_B37","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1080\/10428194.2018.1542149","article-title":"Second allogeneic hematopoietic cell transplantation for relapse after first allografts","volume":"60","author":"Gyurkocza","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2020072411361806900_B38","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/14\/3302\/1749727\/advancesadv2020002222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/14\/3302\/1749727\/advancesadv2020002222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T19:48:25Z","timestamp":1696448905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/14\/3302\/461546\/Treosulfanbased-conditioning-is-feasible-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":38,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002222","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}